Nektar Therapeutics NKTR Strikes $0 79: The Risk Seems Worthwhile At This Price

There are currently 3 sell ratings and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should “sell” NKTR shares. Nektar Therapeutics share price live 0.77, this page displays NASDAQ NKTR stock exchange data. View the NKTR premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nektar Therapeutics real time stock price chart below. You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NKTR quote.

CompanyNektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company. The Company is focused on discovering and developing medicines in the field of immunotherapy. The Company has a research and development pipeline of investigational medicines in oncology and immunology. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain… Intraday Data provided by FACTSET and subject to terms of use. Historical and current end-of-day data provided by FACTSET.

We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive. A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

What is Nektar Therapeutics’s stock style?

Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Basic Materials and Industrials sectors propelled shares higher. Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Healthcare, Technology and Utilities sectors propelled shares higher while losses in the Basic Materials,… Investing.com – U.S. equities were mixed at the close on Tuesday, as gains in the Oil & Gas, Healthcare and Technology sectors propelled shares higher while losses in the Telecoms,…

These returns cover a period from January 1, 1988 through April 3, 2023. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return.

It can also be calculated by dividing the company’s Market Cap by the Net Profit. We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

U.S. shares lower at close of trade; Dow Jones Industrial Average down 2.44%

The group derives revenue from the United States and the Rest of the World. Real-time analyst ratings, insider transactions, earnings data, and more. Nektar Therapeutics has received a consensus rating of Sell. The company’s average rating score is 1.40, and is based on no buy ratings, 2 hold ratings, and 3 sell ratings.

On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category. Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Healthcare, Technology and Consumer Services sectors propelled shares higher while losses in the Oil & Gas,… Investing.com – U.S. equities were higher at the close on Friday, as gains in the Oil & Gas, Financials and Industrials sectors propelled shares higher. Investing.com – U.S. equities were mixed at the close on Friday, as gains in the Oil & Gas, Telecoms and Financials sectors propelled shares higher while losses in the Utilities, Healthcare… Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Consumer Goods, Technology and Consumer Services sectors propelled shares higher while losses in the Oil &… Investing.com – U.S. equities were lower at the close on Tuesday, as losses in the Industrials, Oil & Gas and Technology sectors propelled shares lower.

Full year 2020 earnings released: US$2.49 loss per share (vs US$2.52 loss in FY

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing … Nektar Therapeutics shares rallied late Monday after the biotech drug maker said it was cutting staff by 60% in San Francisco, where the company is based, and shifting its focus to immunology drugs in… Shares of Nektar Therapeutics Inc. were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb’s Opdivo. Shares of Nektar Therapeutics were down 5.7% in premarket trading on Tuesday, the day after the company said it will lay off 70% of its workforce. The technique has proven to be very useful for finding positive surprises.

© 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided ‘as-is’ and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart’s disclaimer. 46 employees have rated Nektar Therapeutics Chief Executive Officer Howard W. Robin on Glassdoor.com. Howard W. Robin has an approval rating of 81% among the company’s employees. Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat’s FREE daily newsletter.

First quarter 2022 earnings: EPS exceeds analyst expectations

Last week, Nektar announced that it has entered into a clinical trial collaboration and supply agreement with pharmaceutical giant… According to 4 analysts, the average rating for NKTR stock is “Sell.” The 12-month stock price forecast is $2.38, which is an increase of 207.69% from the latest price. Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review. Turning to the stock’s technical picture we see that short term indicators suggest on average that NKTR is a 100% Sell.

Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The 1.50% of Nektar Therapeutics’s shares are in the hands of company insiders while institutional holders own 94.80% of the company’s shares.

The Academy Award winner discusses her newest role as Chief Communications Officer for the biotech company and the importance of taking care of your mental & physical health today. All values as of most recently reported quarter unless otherwise noted. Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. CPRX, KALV, LRMR, NKTR, JNCE may prove to be good additions to one’s portfolio.

Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated. Morningstar Quantitative ratings for equities are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Nektar has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea…

That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style. The scores are based on the trading styles of Value, Growth, and Momentum. There’s also a VGM Score (‘V’ for Value, ‘G’ for Growth and ‘M’ for Momentum), which combines the weighted average of the individual style scores into one score. The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. The P/E ratio of Nektar Therapeutics is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. In the past three months, Nektar Therapeutics insiders have sold more of their company’s stock than they have bought.

Nektar Therapeutics’s market cap currently stands at around $147.08 million, with investors looking forward to this quarter’s earnings report slated for May 09, 2023. Analysts project the company’s earnings per share to be -$0.19, which has seen fiscal year 2023 EPS growth forecast to increase to -$0.77 and about -$0.67 for fiscal year 2024. Per the data, EPS growth is expected to be 51.60% for 2023 and 13.00% for the next financial year. 5 Wall Street equities research analysts have issued “buy,” “hold,” and “sell” ratings for Nektar Therapeutics in the last twelve months.

It’s calculated by averaging the closing stock price over the previous 50 trading days. Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding.

Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. In the market, a comparison of Nektar Therapeutics and its peers suggest the former has performed considerably weaker. Data shows NKTR’s intraday price has changed -1.95% in last session and -81.87% over the past year.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends. Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares.

At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.27% per year.

• An industry with a larger percentage of Zacks Rank #1’s and #2’s will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4’s and #5’s.
• 5 equities research analysts have issued 1 year price targets for Nektar Therapeutics’ stock.
• Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Consumer Services, Technology and Healthcare sectors propelled shares higher while losses in the Telecoms,…
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Shares of Nektar Therapeutics Inc. were down 35.9% in trading on Monday after the company announced Friday that it halted development of bempegaldesleukin in combination with Bristol Myers Squibb’s Opdivo.

92.30% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. MarketBeat has tracked 3 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week. Nektar Therapeutics has only been the subject of 4 research reports in the past 90 days. Data are provided ‘as is’ for informational purposes only and are not intended for trading purposes. Data may be intentionally delayed pursuant to supplier requirements.

Also important is the https://1investing.in/ on short interest which shows that short shares stood at 8.21 million on Apr 13, 2023, giving us a short ratio of 0.92. The data shows that as of Apr 13, 2023 short interest in Nektar Therapeutics stood at 4.34% of shares outstanding, with shares short rising to 7.08 million registered in Mar 14, 2023. Current price change has pushed the stock -65.27% YTD, which shows the potential for further growth is there.

Investing.com – U.S. equities were mixed at the close on Thursday, as gains in the Utilities, Financials and Healthcare sectors propelled shares higher while losses in the Oil & Gas,… Investing.com – U.S. equities were mixed at the close on Wednesday, as gains in the Telecoms, Oil & Gas and Consumer Services sectors propelled shares higher while losses in the Technology,… Investing.com – U.S. equities were mixed at the close on Monday, as gains in the Oil & Gas, Financials and Basic Materials sectors propelled shares higher while losses in the Technology,… Investing.com – U.S. equities were higher at the close on Friday, as gains in the Healthcare, Industrials and Consumer Services sectors propelled shares higher.

NKTR underperformed the US Pharmaceuticals industry which returned 1.6% over the past year. Crane Co. will be added to the S&P MidCap 400 effective prior to the open of trading on Tuesday, April 4, replacing PacWest Bancorp which will be moved to the S&P SmallCap 600… Provide specific products and services to you, such as portfolio management or data aggregation. We’d like to share more about how we work and what drives our day-to-day business. Primecap Odyssey Growth’s successful high-conviction multimanager system contributes to its Gold rating. Take your analysis to the next level with our full suite of features, known and used by millions throughout the trading world.

It attempts to reflect the cash profit genesmall scale industries by a company’s operations. 52 week low is the lowest price of a stock in the past 52 weeks, or one year. Nektar Therapeutics 52 week low is $0.603 as of May 01, 2023. 52 week high is the highest price of a stock in the past 52 weeks, or one year. Nektar Therapeutics 52 week high is $5.18 as of May 01, 2023.